While the role of endocannabinoids in the development of schizophrenia, as well as the ability of compounds like CBD to modulate psychosis, are interesting and important topics, here we will focus on CB2-selective modulation as a potential therapeutic for treating schizophrenia after the onset of symptoms. The gene discussed is CNR2; the disease is schizophrenia.